Belite Bio Q3 loss widens on higher costs

Overview

• US retinal drug developer's Q3 net loss widened yr/yr on higher R&D and SG&A costs

• Company's lead drug tinlarebant granted FDA priority review for Stargardt disease, PDUFA date set for Feb 2027

• Belite Bio uplisted to Nasdaq Global Select Market in October 2026

Outlook

• Belite Bio expects FDA decision on tinlarebant by February 12, 2027

• Company submitted tinlarebant marketing applications in Japan, Singapore, UK, and Switzerland

• Company preparing for commercial launch of tinlarebant, pending regulatory approval

Result Drivers

• R&D EXPENSES - Higher R&D costs driven by increased manufacturing expenses for active pharmaceutical ingredients and drug products, as well as consultant fees and sponsorship funding

• SG&A EXPENSES - SG&A costs rose mainly due to higher professional service fees and team expansion

• INTEREST INCOME - Other income increased due to higher interest income from bank deposits and U.S. treasury securities

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Belite Bio, Inc is $217.00, about 39.2% above its November 11 closing price of $155.94

Reuters Recommended Reads

• Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs

• Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)